Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Research
[키워드] acute respiratory distress
acute respiratory syndrome
Administered
administration
Admission
age
Antiviral
antiviral agent
Antiviral treatment
approach
ARDS
assessment
binding
blood biochemical
body temperature
case sery
change
China
Chinese patient
clinical
Clinical outcome
clinical status
clinical trials
conducted
convalescent plasma
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-19
Critical
Critically ill patient
determine
Dilution
discharged
ECMO
Effectiveness
ELISA
end point
enzyme-linked immunosorbent
exposure
extracorporeal membrane oxygenation
failure
Final
finding
Follow-up
greater
hospital
Human plasma
IgG
Ill
Importance
Infection
Infectious disease
laboratory-confirmed
limited sample size
measure
mechanical ventilation
Methylprednisolone
Mortality
neutralization titer
neutralizing antibody
Neutralizing antibody titer
normalized
objective
observation
outcome
pandemic
participant
Patient
patients
plasma
Plasma transfusion
Point
preliminary finding
progression
raise
randomized clinical trials
receiving
recovered patients
Relevance
resolved
Result
SARS-CoV-2
SARS-CoV-2 antibody
SARS-CoV-2–specific antibody
serum antibody
setting
severe pneumonia
Shenzhen
SOFA
SOFA score
Study design
Support
syndrome
therapeutic agent
treated
Treatment
ventilatory
Viral load
were given
with COVID-19
women
[DOI] 10.1001/jama.2020.4783 PMC 바로가기 [Article Type] Research
[DOI] 10.1001/jama.2020.4783 PMC 바로가기 [Article Type] Research